This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday
Gainers
Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume.
Why Poseida Therapeutics Almost Doubled Today, Here Are 75 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday.
Arcutis Biotherapeutics Priced 7.5M Share Public Offering of Common Stock @$20/Share
Arcutis Biotherapeutics, Inc.
Analyst Ratings for Arcutis Biotherapeutics
Over the past 3 months, 4 analysts have published their opinion on Arcutis Biotherapeutics (NASDAQ:ARQT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Why Revlon Shares Jumped 90%; Here Are 83 Biggest Movers From Yesterday
Gainers
Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares jumped 187.3% to close at $48.03 on Monday after gaining around 18% on Friday.
Recap Of Friday’s Biotech Catalysts – End of The Day Summary
The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE…
Arcutis Gets FDA Nod For Plaque Psoriasis Candidate, Sees Commercial Launch In Mid-August
The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ: ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older.
FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, announced today that the U.S. Food and Drug
Arcutis Biotherapeutics Announces Health Canada Accepts For Review New Drug Submission For Roflumilast Cream For Adults And Adolescents With Plaque Psoriasis
Submission supported by positive clinical data from the pivotal Phase 3 DERMIS-1 and DERMIS-2 clinical studies, as well as results from long-term safety studies
If approved, roflumilast cream would be the first and